The long-term use of imatinib may be beneficial for patients with pulmonary arterial hypertension

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1555, 2006-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term benefits of bosentan in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses

By Karavolias George K   Georgiadou Panagiota   Gkouziouta Angeliki   Kariofillis Panagiotis   Karabela Georgia   Tsiapras Dimitrios   Sbarouni Eftihia   Chaidaroglou Antigoni   Degiannis Dimitrios   Adamopoulos Stamatis   Voudris Vassilis  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 12, 2010-12 ,pp. : 1283-1289

Informa Healthcare

Access to resources Recommend Favorite

Imatinib mesylate for the treatment of pulmonary arterial hypertension

By ten Freyhaus Henrik   Dumitrescu Daniel   Berghausen Eva   Vantler Marius   Caglayan Evren   Rosenkranz Stephan  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 119-134

Informa Healthcare

Access to resources Recommend Favorite

Long-term beraprost promising in pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1321, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Long-term immunosuppressant use may be linked to cancer

By  

Reactions Weekly, Vol. 1, Iss. 1329, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite